The tragic death of Oliver Robinson, a 34-year-old who died by suicide in November 2023, has ignited a crucial debate about the regulation of private cannabis clinics in the UK and their impact on vulnerable individuals. Robinson, who struggled with depression and addiction, was prescribed medicinal cannabis by Curaleaf Clinic, a private provider, after exhausting conventional therapies at the Priory, a private mental health facility where he was treated between 2019 and 2022. An inquest concluded that this prescription “probably contributed to his death” and “acted as an obstacle” to him receiving appropriate psychiatric and addiction care.

Oliver's brother, Alexander Robinson, is now spearheading a campaign for stricter controls on the rapidly expanding private cannabis industry. His call for “Oliver’s law” aims to protect vulnerable patients by banning prescriptions for individuals with serious mental illnesses, mandating consultations with NHS mental health teams, and requiring face-to-face assessments for patients. This campaign underscores the urgent need for greater oversight to prevent similar tragedies.

The legalization of medicinal cannabis in 2018, spurred by the case of a child with severe epilepsy, was a landmark moment. However, the current regulatory landscape allows for a significant disparity between NHS and private prescribing practices. While the NHS primarily prescribes licensed cannabis-based medicinal products (CBMPs) for specific conditions like severe epilepsy and multiple sclerosis, private clinics often prescribe unlicensed products, raising concerns about quality control and patient safety.

Data from the NHS Business Services Authority reveals a stark contrast: in 2024, there were 659,293 private prescriptions for unlicensed cannabis products, more than double the 282,920 issued in 2023. This exponential growth raises questions about the motivations driving private prescriptions and the potential for exploitation of vulnerable patients. Dr. Pavan Chahl, a psychiatrist, testified at Robinson's inquest that medicinal cannabis should not be prescribed to individuals with a history of severe psychiatric disorder, citing a lack of evidence for its effectiveness in treating depression and evidence suggesting it can worsen the condition.

The case of Oliver Robinson exposes a systemic issue: the potential for private healthcare providers to prioritize profit over patient well-being. The lack of stringent regulations and oversight creates a breeding ground for questionable prescribing practices, particularly when it comes to mental health. The rapid expansion of the private cannabis industry demands immediate action to ensure that patient safety is paramount.